Tapan M. Kadia MD

PubMed

• Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
  Naval Daver, Jayastu Senapati, Hagop M Kantarjian, Bofei Wang, Patrick K Reville
  Clinical Cancer Research. 2025-06-13
• 2 citations
  TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation.
  Konstantinos Lontos, Rima M Saliba, Rashmi Kanagal-Shamanna, Gonca Özcan, Jeremy Ramdial
  Blood Advances. 2025-06-10
• Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia.
  Jayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, Indraneel Deshmukh, Gautam Borthakur
  Bone Marrow Transplantation. 2025-06-01

Journal Articles

• Response Kinetics and Factors Predicting Survival in Core-Binding Factor Leukemia  
  Hagop Kantarjian, Gautam Borthakur, Tapan Kadia, Nature

Abstracts/Posters

• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Di...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II TrialClinically Relevant Abstract
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pt...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) Regimen Results in Better Molecular Response and Relapse-Free Survival in Core Binding Factor Acute ...
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm)
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Tapan M. Kadia, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Less Is More 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older P... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia – Final Results of a Prospective Phase 2 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all